Next Article in Journal
Assessing the Attitudes and Clinical Practices of Ohio Dentists Treating Patients with Dental Anxiety
Next Article in Special Issue
Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)
Previous Article in Journal
Marginal Vertical Fit along the Implant-Abutment Interface: A Microscope Qualitative Analysis
Previous Article in Special Issue
Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ)
Article Menu

Export Article

Open AccessReview
Dent. J. 2016, 4(4), 32; doi:10.3390/dj4040032

Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma

1
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria
2
Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany
3
Konzept Pharma Service GmbH, 31084 Freden, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Patrick Schmidlin
Received: 2 August 2016 / Revised: 27 August 2016 / Accepted: 19 September 2016 / Published: 27 September 2016
(This article belongs to the Special Issue New Cancer and Osteoporosis Therapies and Osteocrosis of the Jaws)
View Full-Text   |   Download PDF [670 KB, uploaded 27 September 2016]   |  

Abstract

Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients. View Full-Text
Keywords: osteonecrosis; bisphosphonate; denosumab; multiple myeloma; breast cancer; prostate cancer osteonecrosis; bisphosphonate; denosumab; multiple myeloma; breast cancer; prostate cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rugani, P.; Walter, C.; Kirnbauer, B.; Acham, S.; Begus-Nahrman, Y.; Jakse, N. Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent. J. 2016, 4, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Dent. J. EISSN 2304-6767 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top